在重症患者中最佳的铁素剂量方案:基于功能和感染类型的人口药理动力学和剂量模拟
Yifan Wang1,2, Fen Yao2, Shenglong Chen3
1Department of Critical Care Medicine, Shenzhen People's Hospital, The Second Clinical Medical College of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518020, People's Republic of China.
在重症监护病房 (ICU) 患者中,标准的提科普拉宁剂量是不够的. 这项研究提供了基于估计的淋巴细胞过率 (eGFR) 和感染类型的量身定制剂量方案,以获得最佳的 teicoplanin 治疗.
科学领域:
- 药理动力学和药理动力学
- 传染性疾病 传染性疾病
- 关键护理医学 关键护理医学
背景情况:
- 泰科普拉宁是治疗重症病房 (ICU) 患者严重感染的关键抗生素.
- 优化teicoplanin剂量对于达到治疗度和改善患者的治疗结果至关重要.
- 现有的剂量指南可能无法充分考虑ICU环境中的患者特定因素.
研究的目的:
- 在ICU患者中开发teicoplanin的种群药动力学模型.
- 通过蒙特卡洛模拟来确定最佳的提科普拉宁剂量方案.
- 根据功能和感染类型分层提供基于证据的剂量建议.
主要方法:
- 一项前性观察性研究,涉及151名ICU患者和347个血样本.
- 开发一个双部件人群药动力学模型,用于teicoplanin.
- 蒙特卡洛模拟用于评估各种剂量方案实现目标 (PTA) 的概率.
主要成果:
- 泰科普拉宁的全身清除 (CL) 受到估计的球过率 (eGFR) 的显著影响.
- 在大多数ICU患者中,标准的提科普拉宁剂量方案不足以达到目标度最低值 (Cmin).
- 优化剂量策略,包括调整剂量和加载剂量,对于EGFR>30mL/min/1.73m2的患者来说是必要的.
结论:
- 标准的提科普拉宁剂量方案不足以实现一般ICU患者的治疗目标.
- 这项研究基于eGFR和感染特征为ICU患者提供了具体的,分层的tiacoplanin剂量建议.
- 实施这些量身定制的治疗方案可以提高在重症患者中提克洛普拉宁治疗的疗效.
更多相关视频
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
相关概念视频
Acute Pyelonephritis II: Diagnostic Studies and Management
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
